Hope for our health

Hope for our health

27-06-2014 | Research

The development of new cures for severe diseases and the aging of the population have blown up healthcare costs. Fortunately, new tools and technologies promise to enhance productivity and improve healthcare quality. Henk Grootveld, Portfolio Manager of Rolinco and Robeco Global Growth Trends Equities, and Steef Bergakker, Robeco’s Trend Analyst, discuss these exciting new developments and the arising investment opportunities.

  • Henk Grootveld
    Portfolio Manager/ Head Trends Investing

Modern medicine has been very successful in treating once fatal diseases. Infant diseases have almost been erased thanks to pediatric vaccines. Once lethal diseases like tuberculosis, diphtheria and cholera have been tamed and even hard-to-crack HIV has been transformed from a fatal disease into a chronic one. There is also hope of further successes in the future. In cancer, for example, a new breakthrough therapy has been discovered that looks to be defeating at least some of the many different types of cancer.

Stay informed on our latest insights with monthly mail updates
Stay informed on our latest insights with monthly mail updates

Explosion of healthcare costs

Unfortunately, this success has had an unwelcome side-effect: an explosion of healthcare costs. The combination of more diseases that can be treated and more people that have access to healthcare has caused healthcare costs to outgrow GDP for decades. In many developed nations healthcare spending already exceeds 10% of GDP and is still climbing. 

The demand for healthcare is virtually guaranteed to soar over the coming decades, simply because healthcare demand is positively correlated to age and the proportion of elderly people is inexorably growing in virtually every region of the world. If we cannot find ways to dramatically increase healthcare productivity, costs will run out of control sooner rather than later and healthcare will become unaffordable.

New ways to raise productivity

Fortunately, exciting new tools and technologies that promise huge productivity improvements in healthcare are now rapidly evolving and gaining critical mass. Examples are DNA testing, diagnostic imaging technology, artificial intelligence and personalized medicine. For investors, there are three trends from which we can benefit, i.e. fragmentation, customization and decentralization.

Subjects related to this article are:

Important legal information

The content displayed on this website is exclusively directed at qualified investors, as defined in the swiss collective investment schemes act of 23 june 2006 ("cisa") and its implementing ordinance, or at “independent asset managers” which meet additional requirements as set out below. Qualified investors are in particular regulated financial intermediaries such as banks, securities dealers, fund management companies and asset managers of collective investment schemes and central banks, regulated insurance companies, public entities and retirement benefits institutions with professional treasury or companies with professional treasury.

The contents, however, are not intended for non-qualified investors. By clicking "I agree" below, you confirm and acknowledge that you act in your capacity as qualified investor pursuant to CISA or as an “independent asset manager” who meets the additional requirements set out hereafter. In the event that you are an "independent asset manager" who meets all the requirements set out in Art. 3 para. 2 let. c) CISA in conjunction with Art. 3 CISO, by clicking "I Agree" below you confirm that you will use the content of this website only for those of your clients which are qualified investors pursuant to CISA.

Representative in Switzerland of the foreign funds registered with the Swiss Financial Market Supervisory Authority ("FINMA") for distribution in or from Switzerland to non-qualified investors is Robeco Switzerland AG, Josefstrasse 218, 8005 Zürich, and the paying agent is UBS Switzerland AG, Bahnhofstrasse 45, 8001 Zürich. Please consult for a list of FINMA registered funds.

Neither information nor any opinion expressed on the website constitutes a solicitation, an offer or a recommendation to buy, sell or dispose of any investment, to engage in any other transaction or to provide any investment advice or service. An investment in a Robeco/Robeco Switzerland product should only be made after reading the related legal documents such as management regulations, articles of association, prospectuses, key investor information documents and annual and semi-annual reports, which can be all be obtained free of charge at this website, at the registered seat of the representative in Switzerland, as well as at the Robeco/Robeco Switzerland offices in each country where Robeco has a presence. In respect of the funds distributed in Switzerland, the place of performance and jurisdiction is the registered office of the representative in Switzerland.

This website is not directed to any person in any jurisdiction where, by reason of that person's nationality, residence or otherwise, the publication or availability of this website is prohibited. Persons in respect of whom such prohibitions apply must not access this website.

I Disagree